UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*
	NANTKWEST, INC. (Name of Issuer)
	Common Stock, \$0.0001 par value (Title of Class of Securities)
	63016Q 102 (CUSIP Number)
	December 31, 2016 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule	pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)	
☐ Rule 13d-1(c)	
⊠ Rule 13d-1(d)	

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP N	lo. 63016Q	10	2	Page 2 of 5 Pages	
1	NAMES C)F F	REPORTING PERSONS		
	Sorrento	The	erapeutics, Inc.		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) \square (B) \square				
3	SEC USE ONLY				
4	CITIZENS	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware	Delaware			
		5	SOLE VOTING POWER		
NUMBER OF			0		
SH	IARES	6	SHARED VOTING POWER		
	FICIALLY NED BY		0		
	ACH ORTING	7	SOLE DISPOSITIVE POWER		
PE	RSON		0		
V	VITH	8	SHARED DISPOSITIVE POWER		
			0		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	0				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	0%				
12	TYPE OF	RE	PORTING PERSON (SEE INSTRUCTIONS)		
	CO				
	1				

(a)	Nam	e of Issuer				
	Nan	Kwest, Inc.				
(b)	Addı	ress of Issuer's Principal Executive Offices				
		John Hopkins Court Diego, California 92121				
2.						
(a)	Name of Person Filing					
	Sorr	ento Therapeutics, Inc. (the "Reporting Person")				
(b)	Address of Principal Business office or, if None, Residence					
) Judicial Drive Diego, CA 92121				
(c)) Citizenship					
	The	Reporting Person is a corporation organized under the laws of the State of Delaware.				
(d)	Title of Class of Securities					
	Com	mon Stock, \$0.0001 par value				
(e)	CUSIP Number					
	6301	6Q 102				
3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:					
	(a)	\square Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);				
	(b)	\square Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);				
	(c)	\square Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);				
	(d)	\square Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);				
	(e)	☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);				
	(f)	\square An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);				
	(g)	\square A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);				

Item 1.

Item

Item

	Page 4 of 5 Pages						
	(h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);						
	(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);						
	(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);						
	(k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:						
Item 4.	Ownership.						
	(a) Amount beneficially owned: 0						
	(b) Percent of class: 0%						
	(c) Number of shares as to which the person has:						
	(i) Sole power to vote or to direct the vote: 0						
	(ii) Shared power to vote or to direct the vote: 0						
	(iii) Sole power to dispose or to direct the disposition of: 0						
	(iv) Shared power to dispose or to direct the disposition of: 0						
Item 5.	Ownership of Five Percent or Less of a Class.						
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following \boxtimes						
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.						
	N/A						
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.						
	N/A						
Item 8.	Identification and Classification of Members of the Group.						
	N/A						
Item 9.	Notice of Dissolution of Group.						
	N/A						
Item 10.	Certifications.						
	N/A						

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2017

Sorrento Therapeutics, Inc.

By: /s/ Henry Ji, Ph.D.

Name: Henry Ji, Ph.D.

Title: President and Chief Executive Officer